Agios Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis
Agios Pharmaceuticals, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). A validated rare disease player with first-in-class PK activators driving near-term revenue growth and multiple catalyst events into 2026. Agios demonstrates strong execution with a landmark FDA approval of AQVESME and active clinical pipeline across multiple indications. The company has achieved commercial-stage status with early launch momentum, though it.
What is Agios Pharmaceuticals, Inc.'s industry? Agios Pharmaceuticals, Inc. (agios.com) operates in Biopharmaceutical/Rare Diseases. AskCyborg classifies Agios Pharmaceuticals, Inc. under Biopharmaceutical/Rare Diseases in its company registry.
Agios Pharmaceuticals is a commercial-stage biopharmaceutical company pioneering therapies for genetically defined rare diseases, with a core focus on cellular metabolism and pyruvate kinase (PK) activation. The compa...
Cyborg Score thesis
A validated rare disease player with first-in-class PK activators driving near-term revenue growth and multiple catalyst events...
Read the full analyst-debate transcript →Get the Latest Agios Pharmaceuticals, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAgios Pharmaceuticals, Inc. Overview
Pro stress-test →Agios Pharmaceuticals is a commercial-stage biopharmaceutical company pioneering therapies for genetically defined rare diseases, with a core focus on cellular metabolism and pyruvate kinase (PK) activation. The company achieved a historic milestone with the 2025 U.S. FDA approval of AQVESME (mitapivat) for thalassemia, marking the first disease-modifying therapy for this blood disorder.
Strategic Profile
Pro stress-test →Agios positions itself as the leader in PK activation with a growing pipeline addressing high-value rare disease indications including sickle cell disease, myelodysplastic syndromes, and other hemolytic anemias. The company leverages deep expertise in cellular metabolism and strong partnerships with patient communities to drive differentiated product development and commercialization.
Competitive Landscape
Pro stress-test →Agios competes in the rare disease and hematology treatment space against companies like Vicore Pharma Holding and others pursuing hemolytic anemia and genetic disease therapies. Its differentiated position stems from proprietary expertise in pyruvate kinase activation and established first-mover advantage with AQVESME/PYRUKYND in thalassemia.
Industry Context
Agios Pharmaceuticals, Inc. operates in Biopharmaceutical/Rare Diseases.
Key facts
Founded: 2007 · Headquarters: Cambridge, Massachusetts · Employees: 488 · Revenue: $44.8M · Market cap: $1.57B